Skip to main content

Table 3 Work productivity and activity impairment questionnaire

From: Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis

Instrument Subscale/ ETN + MTX DMARD + MTX P value*
 Time on Therapy Mean Score (% Improvement from Baseline) (N)  
Percent activity impairment due to health    
 Baseline 58.6 (0%) (N = 197) 58.6 (0%) (N = 103)  
 Week 16 30.0 (48.7%) (N = 186) 41.0 (29.3%) (N = 83) < 0.001
Percent impairment while working due to health problem    
 Baseline 48.9 (0%) (N = 62) 51.4 (0%) (N = 37)  
 Week 16 24.1 (49.6%) (N = 54) 37.3 (23.6%) (N = 26) 0.012
Percent overall work impairment due to health problem    
 Baseline 52.3 (0%) (N = 61) 56.3 (0%) (N = 37)  
 Week 16 25.1 (51.0%) (N = 53) 41.6 (22.0%) (N = 26) 0.004
Percent work time missed due to health    
 Baseline 10.6 (0%) (N = 63) 14.9 (0%) (N = 37)  
 Week 16 2.04 (80.7%) (N = 55) 10.7 (21.7%) (N = 26) 0.002
  1. General Health at Baseline and Following 16 Weeks of Therapy in Asia-Pacific Rheumatoid Arthritis Patients Treated With ETN + MTX versus DMARD + MTX (Observed Case Analysis).
  2. DMARD: Disease Modifying Antirheumatic Drug; ETN: etanercept; MTX: methotrexate.
  3. *ANCOVA, considering the factors ‘baseline score + therapy + country’.